Literature DB >> 25987332

[Conservative therapy of erectile dysfunction].

M Trottmann1, J Marcon, S Pompe, D Strobach, A J Becker, C G Stief.   

Abstract

The erectile dysfunction (ED) with a prevalence of 19.2% and a steep age-related increase up to 53.4% in men over 70 years is a common sexual disorder. Especially after market launch of the phosphodiesterase 5 inhibitors the possibility of an easy-to-use and well-tolerated therapy is available. In case of nonresponse, vasoactive substances can be applied in different forms. In case of an additional hypogonadism, testosterone substitution is indicated. Simultaneously the causes of ED should always be treated, including a change of lifestyle with elimination of exogenous noxa. The use of mechanic tools as single or combination therapy can lead to improved erection. This article provides a critical overview of the latest conservative therapy options, it explains previous unsuccessful therapeutic trials and gives an outlook into potential ED therapy concepts of the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25987332     DOI: 10.1007/s00120-015-3794-3

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  43 in total

1.  Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte.

Authors:  R Sakakibara; T Hattori; T Uchiyama; T Suenaga; H Takahashi; T Yamanishi; K Egoshi; N Sekita
Journal:  J Auton Nerv Syst       Date:  2000-03-15

Review 2.  Treating erectile dysfunction when PDE5 inhibitors fail.

Authors:  Chelsea N McMahon; Christopher J Smith; Ridwan Shabsigh
Journal:  BMJ       Date:  2006-03-11

Review 3.  Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis.

Authors:  Alexander Tsertsvadze; Howard A Fink; Fatemeh Yazdi; Roderick MacDonald; Anthony J Bella; Mohammed T Ansari; Chantelle Garritty; Karla Soares-Weiser; Raymond Daniel; Margaret Sampson; Steven Fox; David Moher; Timothy J Wilt
Journal:  Ann Intern Med       Date:  2009-11-03       Impact factor: 25.391

4.  Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial.

Authors:  E J Keogh; G R Watters; C M Earle; C J Carati; Z S Wisniewski; G S Tulloch; D J Lord
Journal:  J Urol       Date:  1989-09       Impact factor: 7.450

Review 5.  Erectile dysfunction in diabetes mellitus.

Authors:  Lasantha S Malavige; Jonathan C Levy
Journal:  J Sex Med       Date:  2009-02-10       Impact factor: 3.802

6.  Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use.

Authors:  Javier Romero Otero; Borja García Gómez; José Medina Polo; Estíbaliz Jiménez Alcaide; Eduardo García Cruz; Andrea Sallent Font; Alfredo Rodríguez Antolín
Journal:  Urology       Date:  2014-04-16       Impact factor: 2.649

Review 7.  Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction.

Authors:  W Wallace Dinsmore; Michael G Wyllie
Journal:  BJU Int       Date:  2008-05-15       Impact factor: 5.588

Review 8.  Molecular pharmacotherapeutic targeting of PDE5 for preservation of penile health.

Authors:  Arthur L Burnett
Journal:  J Androl       Date:  2007-10-17

Review 9.  Potent natural aphrodisiacs for the management of erectile dysfunction and male sexual debilities.

Authors:  Singh Akhand Pratap; Singh Rajender
Journal:  Front Biosci (Schol Ed)       Date:  2012-01-01

10.  Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction.

Authors:  James G McMurray; Robert A Feldman; Stephen M Auerbach; Herb Deriesthal; Neal Wilson
Journal:  Ther Clin Risk Manag       Date:  2007-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.